Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.63 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12181845 | 0.86 | RXRA (0.80) | RXRAPPARG | |
| SCHEMBL30389970 | 0.86 | RXRA (0.80) | RXRAPPARG | |
| SCHEMBL18697015 | 0.82 | RXRA (0.74) | RXRAPPARG | |
| SCHEMBL30389830 | 0.82 | RXRA (0.74) | RXRAPPARG | |
| SCHEMBL29068250 | 0.78 | RXRA (1.00) | RXRAPPARGCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL17119516 | 0.78 | RXRA (1.00) | RXRAPPARGCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL30390283 | 0.78 | RXRA (1.00) | RXRAPPARGCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL19542342 | 0.76 | RXRA (0.81) | RXRAPPARGCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL8154646 | 0.76 | RXRA (0.44) | RXRAPPARGLCKPRKACAPRKACG | |
| SCHEMBL8154649 | 0.76 | RXRA (0.44) | RXRAPPARGLCKPRKACAPRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266842-A1 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | US ARMY, SECRETARY OF THE ARMY | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266842-A1 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | RXRG, RXRB, RXRA | RXRA 3/4885PPARG 43/4885LCK 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.